CERo Therapeutics Holdings (CERO): שולי רווח נקי ממכירות

cero.bio - לוגו גרפי של המנפיק CERO

CERo Therapeutics (CERO) develops immuno-oncology platforms using a fabless model, outsourcing T-cell production to third-party contractors in the US. The net profit margin history reflects current business dynamics, with the latest figure standing at 0.00. Rising R&D costs currently limit scalability due to a lack of operating leverage. Capitalization is expected to be driven by insurance reimbursements for the innovative CER-T therapy used in tumor treatment.

רווחיות מכירות נקייה cero.bio (CERO): לתקופה 21.02.2024 - 08.11.2025

CERo Therapeutics Holdings, Inc. (CERO) - פילוחי מדדים ודוחות פיננסיים

הערכת שווי פונדמנטלית של החברה:cero.bio - CERO
מוצרים מוגמרים של CERo Therapeutics Holdings

Net profit margin determines the efficiency of converting revenue into bottom-line income. By analyzing the marginal sales profile, an investor assesses the business's resilience to operating expenses. The metric is calculated as the ratio of net profit to total sales volume. For CERo Therapeutics (CERO), this metric is critical due to the labor-intensive nature of T-cell modification. The lack of assembly-line scaling in immunotherapy limits margin growth due to the high proportion of manual labor.